Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Express Scripts Holding Co    ESRX

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Express Scripts Holding Co : Express Scripts Sues Ernst & Young Alleging Document Theft

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/16/2013 | 12:36am CET
   By Jon Kamp and Michael Rapoport 
 

Pharmacy-benefit giant Express Scripts Holding Co. (ESRX) has filed a lawsuit against accounting firm Ernst & Young LLP and a former employee for allegedly stealing at least 20,000 pages of data containing confidential information and trade secrets.

St. Louis-based Express Scripts hired E&Y to provide consulting services while combining its business with Medco Health Solutions. Express Scripts bought Medco last year to form the largest pharmacy-benefit manager by prescriptions handled.

These firms, known as PBMs, managed drug benefits for health plans and corporate clients, using their buying clout to secure rebates from drug manufacturers. Express Scripts said in the lawsuit that its investigation did not show E&Y's actions affecting any patient or protected health information.

But Express Scripts did accuse the big-four accounting giant of taking "competitively sensitive cost and pricing information" and "highly proprietary" documents involving business and integration strategies, projections and performance metrics.

Express Scripts didn't have a comment on the matter beyond the content of the court filing, which seeks "substantial punitive damages," and to stop E&Y from using or disclosing the information at issue. The lawsuit was filed Thursday in the Circuit Court in St. Louis County, Mo., and reviewed by Dow Jones Newswires.

E&Y in a statement Friday confirmed there was a violation of company policies, and that the individual "at the center of these allegations"--who the Express Scripts lawsuit said was a Health Care IT Partner named Donald Gravlin--"is no longer with the firm."

But E&Y also said it will "vigorously contest the claims" in the lawsuit. The accounting firm noted it "immediately took all necessary steps" to secure the data at issue once it became aware of the matter, and that it's not aware of any instance where the data was used inappropriately or transmitted to a third party.

According to Express Scripts' allegations, an investigation launched last August determined Mr. Gravlin was sending confidential information from another E&Y employee's Express Scripts email account to an outside email account. The company accused him of "sneaking into Express Scripts' headquarters and stealing confidential and proprietary information" for months.

The PBM also alleged that E&Y was motivated to facilitate this activity because it stood to gain from the confidential information, which could be used to grow and develop additional business both with Express Scripts and competitors.

Attempts to reach Mr. Gravlin late Friday were unsuccessful.

E&Y said it believes its prompt action to secure the data prevented any harm to Express Scripts. "Ernst & Young takes client confidentiality seriously," the company said. "We are fully committed to following our clients' security protocols."

Express Scripts uses PricewaterhouseCoopers for auditing work and Deloitte for tax accounting.

Write to Jon Kamp at jon.kamp@dowjones.com

Corrections & Amplifications

This was corrected at 7:47 p.m. EST because the original incorrectly identified the accounting firm in the last paragraph as PricewaterhouseCoopers. That firm does auditing work for Express Scripts, and the tax accountant is Deloitte.

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on EXPRESS SCRIPTS HOLDING CO
02/22 EXPRESS SCRIPTS HOLDING CO : Post Earnings Coverage as Express Scripts' Adjusted..
02/17 EXPRESS SCRIPTS : CEO addresses drug pricing "misinformation"
02/16 EXPRESS SCRIPTS : Fights Back Against Irresponsible Drug Pricing; Holds U.S. Dru..
02/15 EXPRESS SCRIPTS HOLDING COMPANY (NAS : ESRX) Files An 8-K Results of Operations ..
02/14 EXPRESS SCRIPTS : Management's Discussion and Analysis of Financial Condition an..
02/14DJEXPRESS SCRIPTS : Revenue Falls
02/14 EXPRESS SCRIPTS HOLDING CO. : Regulation FD Disclosure, Financial Statements and..
02/14 EXPRESS SCRIPTS : beats 4Q profit forecasts
02/14 EXPRESS SCRIPTS : Announces 2016 Fourth Quarter and Full Year Results
02/14 EXPRESS SCRIPTS : Today
More news
Sector news : Drug Retailers - NEC
02/16DJRetail CEOs Meet With Trump Over Border Tax Concerns -- Update
02/15DJRetail CEOs Meet With Trump Over Border Tax Concerns
02/14 Exclusive - Trump to meet with retail CEOs on taxes, infrastructure
02/09DJCVS HEALTH : Profit Rises, Helped by Pharmacy Strength -- Update
02/09DJCVS HEALTH : Profit Rises, Helped by Pharmacy Strength
More sector news : Drug Retailers - NEC
News from SeekingAlpha
02/24 Tracking Larry Robbins' Glenview Capital Management Portfolio - Q4 2016 Updat..
02/23 Tracking Wallace Weitz's Weitz Investment Management Portfolio - Q4 2016 Upda..
02/17 Tracking Glenn Greenberg's Brave Warrior Advisors Portfolio - Q4 2016 Update
02/15 Express Scripts, Inc. 2016 Q4 - Results - Earnings Call Slides
02/15 Express Scripts Holding (ESRX) Q4 2016 Results - Earnings Call Transcript
Advertisement
Financials ($)
Sales 2017 102 482 M
EBIT 2017 6 749 M
Net income 2017 2 979 M
Debt 2017 11 594 M
Yield 2017 -
P/E ratio 2017 14,14
P/E ratio 2018 12,38
EV / Sales 2017 0,54x
EV / Sales 2018 0,51x
Capitalization 43 460 M
More Financials
Chart EXPRESS SCRIPTS HOLDING CO
Duration : Period :
Express Scripts Holding Co Technical Analysis Chart | ESRX | US30219G1085 | 4-Traders
Full-screen chart
Technical analysis trends EXPRESS SCRIPTS H...
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 23
Average target price 80,7 $
Spread / Average Target 12%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Timothy C. Wentworth President, Chief Executive Officer & Director
George Paz Chairman
Christine Houston Senior Vice President-Operations
Eric R. Slusser Chief Financial Officer & Executive Vice President
Steven B. Miller Chief Medical Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
EXPRESS SCRIPTS HOLDIN..4.01%43 460
WALGREENS BOOTS ALLIAN..5.86%94 146
CVS HEALTH CORP3.26%83 502
MCKESSON CORPORATION7.40%32 115
CARDINAL HEALTH INC14.13%26 022
AMERISOURCEBERGEN CORP..17.87%19 931
More Results